See more : Construtora Adolpho Lindenberg S.A. (CALI3.SA) Income Statement Analysis – Financial Results
Complete financial analysis of Nevro Corp. (NVRO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nevro Corp., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Radiko Holdings Corp. (GEATF) Income Statement Analysis – Financial Results
- Delivery Hero SE (DELHY) Income Statement Analysis – Financial Results
- GuangYuYuan Chinese Herbal Medicine Co., Ltd. (600771.SS) Income Statement Analysis – Financial Results
- Gujarat Cotex Limited (GUJCOTEX.BO) Income Statement Analysis – Financial Results
- Thong Guan Industries Berhad (7034.KL) Income Statement Analysis – Financial Results
Nevro Corp. (NVRO)
About Nevro Corp.
Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. It also provides 10 kHz Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was incorporated in 2006 and is headquartered in Redwood City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 425.17M | 406.37M | 386.91M | 362.05M | 390.26M | 387.29M | 326.67M | 228.50M | 69.61M | 32.57M | 23.50M | 18.15M |
| Cost of Revenue | 135.11M | 130.00M | 120.86M | 112.15M | 121.91M | 113.97M | 98.98M | 75.43M | 28.12M | 11.28M | 9.47M | 7.53M |
| Gross Profit | 290.06M | 276.37M | 266.04M | 249.90M | 268.35M | 273.32M | 227.69M | 153.07M | 41.49M | 21.30M | 14.03M | 10.62M |
| Gross Profit Ratio | 68.22% | 68.01% | 68.76% | 69.02% | 68.76% | 70.57% | 69.70% | 66.99% | 59.60% | 65.38% | 59.69% | 58.53% |
| Research & Development | 54.42M | 53.07M | 47.67M | 45.60M | 59.02M | 48.46M | 37.56M | 33.73M | 21.38M | 19.82M | 20.35M | 15.66M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 266.61M | 219.71M | 142.42M | 82.47M | 29.78M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 334.70M | 322.14M | 309.31M | 267.15M | 305.81M | 266.61M | 219.71M | 142.42M | 82.47M | 29.78M | 18.83M | 14.09M |
| Other Expenses | 246.00K | 511.00K | -814.00K | -495.00K | -697.00K | -1.16M | 1.07M | -1.10M | -1.74M | -1.88M | -654.00K | 186.00K |
| Operating Expenses | 389.37M | 375.20M | 356.98M | 312.75M | 364.83M | 315.07M | 257.27M | 176.15M | 103.85M | 49.60M | 39.18M | 29.75M |
| Cost & Expenses | 524.48M | 505.20M | 477.84M | 424.90M | 486.73M | 429.03M | 356.25M | 251.59M | 131.97M | 60.88M | 48.65M | 37.28M |
| Interest Income | 14.17M | 4.02M | 671.00K | 2.96M | 6.02M | 4.87M | 3.16M | 1.69M | 575.00K | 0.00 | 153.00K | 139.00K |
| Interest Expense | 8.01M | 6.43M | 19.75M | 21.81M | 10.93M | 10.40M | 9.90M | 6.39M | 2.73M | 16.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 11.54M | 10.33M | 8.68M | 8.19M | 7.80M | 3.89M | 2.51M | 1.72M | 614.00K | 96.00K | 47.00K | 39.00K |
| EBITDA | -78.31M | 21.02M | -102.40M | -52.21M | -83.36M | -37.86M | -22.84M | -22.04M | -62.92M | -30.09M | -25.10M | -19.09M |
| EBITDA Ratio | -18.42% | -50.16% | -18.33% | -17.36% | -24.72% | -10.78% | -9.05% | -9.55% | -89.60% | -86.90% | -106.83% | -105.18% |
| Operating Income | -99.31M | -98.84M | -90.93M | -62.85M | -96.48M | -41.74M | -29.58M | -23.08M | -62.37M | -28.31M | -25.15M | -19.13M |
| Operating Income Ratio | -23.36% | -24.32% | -23.50% | -17.36% | -24.72% | -10.78% | -9.05% | -10.10% | -89.60% | -86.90% | -107.03% | -105.40% |
| Total Other Income/Expenses | 1.45M | -1.90M | -19.89M | -19.35M | -5.61M | -6.69M | -5.67M | -7.07M | -3.90M | -1.90M | -501.00K | 325.00K |
| Income Before Tax | -97.86M | 4.26M | -130.83M | -82.20M | -102.09M | -48.44M | -35.25M | -30.16M | -66.27M | -30.20M | -25.65M | -18.81M |
| Income Before Tax Ratio | -23.02% | 1.05% | -33.81% | -22.70% | -26.16% | -12.51% | -10.79% | -13.20% | -95.20% | -92.72% | -109.16% | -103.61% |
| Income Tax Expense | -5.65M | 1.26M | 534.00K | 868.00K | 1.60M | 768.00K | 1.41M | 1.62M | 1.17M | 478.00K | 362.00K | 162.00K |
| Net Income | -92.21M | 3.00M | -131.36M | -83.07M | -103.69M | -49.21M | -36.66M | -31.78M | -67.43M | -30.68M | -26.01M | -18.97M |
| Net Income Ratio | -21.69% | 0.74% | -33.95% | -22.94% | -26.57% | -12.70% | -11.22% | -13.91% | -96.88% | -94.19% | -110.70% | -104.50% |
| EPS | -2.56 | 0.09 | -3.77 | -2.47 | -3.37 | -1.64 | -1.25 | -1.12 | -2.54 | -6.91 | -38.27 | -27.90 |
| EPS Diluted | -2.56 | 0.08 | -3.77 | -2.47 | -3.37 | -1.64 | -1.25 | -1.12 | -2.54 | -6.91 | -38.27 | -27.90 |
| Weighted Avg Shares Out | 35.98M | 35.32M | 34.82M | 33.68M | 30.80M | 30.05M | 29.42M | 28.49M | 26.58M | 4.44M | 679.77K | 679.77K |
| Weighted Avg Shares Out (Dil) | 35.98M | 35.53M | 34.82M | 33.68M | 30.80M | 30.05M | 29.42M | 28.49M | 26.58M | 4.44M | 679.77K | 679.77K |
Nevro to Report First Quarter 2023 Financial Results
Company to Host Conference Call on Wednesday, April 26, 2023 at 1:30 pm PT / 4:30 pm ET REDWOOD CITY, Calif. , March 29, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions...
Nevro (NVRO) Q4 Earnings Lag Estimates, Revenues Beat
Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in Q4, partly owing to robust domestic performance.
Nevro Corporation (NVRO) Q4 2022 Earnings Call Transcript
Nevro Corporation (NYSE:NVRO ) Q4 2022 Earnings Conference Call February 16, 2023 4:30 PM ET Company Participants Julie Dewey - Chief Corporate Communications and Investor Relations Officer Keith Grossman - Chairman, CEO and President Rod MacLeod - Chief Financial Officer...
Nevro (NVRO) Reports Q4 Loss, Tops Revenue Estimates
Nevro (NVRO) delivered earnings and revenue surprises of -10.20% and 0.52%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Nevro (NVRO): Can Its 5.1% Jump Turn into More Strength?
Nevro (NVRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Nevro to Present at Citi's 2023 Healthcare Services, Medtech, Tools & HCIT Conference
Wednesday, March 1, 2023 at 8:45 am Eastern Time REDWOOD CITY, Calif. , Feb. 1, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that...
Nevro to Report Fourth Quarter and Full-Year 2022 Financial Results
Company to Host Conference Call on Thursday, February 16, 2023 at 1:30 pm PT / 4:30 pm ET REDWOOD CITY, Calif. , Jan. 19, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing...
Nevro's (NVRO) Preliminary Q4 Revenues Solid, Issues '23 Outlook
Nevro's (NVRO) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its PDN business.
3 Reasons to Retain Nevro (NVRO) Stock in Your Portfolio
Investors continue to be optimistic about Nevro (NVRO), owing to its R&D edge.
Nevro: Recent Developments Corroborate Breakout, Revise To Buy
Obtained FDA approval for its Senza HFX iQ spinal cord stimulation system in October. Revenue growth was reported at 8% YoY and lifted to $100.5mm on adjusted EBITDA of negative $3.8mm.
Source: https://incomestatements.info
Category: Stock Reports